TALAPRO-2

Presented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer

Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…

ASCO 2023: novel treatment combination shows promise as first-line treatment in patients with metastatic castration-resistant prostate cancer

New additional data from the phase 3 TALAPRO-2 study, presented today at the 2023 Annual Meeting of the American Society of…